Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells.

Oncotarget - 30 Aug 2016

Kwan Suet-Yan, Cheng Xuanjin, Tsang Yvonne T M, Choi Jong-Sun, Kwan Suet-Ying, Izaguirre Daisy I, Kwan Hoi-Shan, Gershenson David M, Wong Kwong-Kwok

Abstract excerpt

Inactivating mutations in ARID1A are found in a broad spectrum of cancer types, with the highest frequency in gynecologic cancers. However, therapeutic strategies targeting ARID1A-mutant cancer cells remain limited. In this study, we aimed to identify drugs sensitivities in ARID1A-mutant cancer cell lines. By analyzing the Genomics of Drug Sensitivity in Cancer database, we found that ARID1A-mutant cancer cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Clear Cell
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrazines

Share to Inhibitory Concentration 50

Share to Ovarian Neoplasms

Share to Oxidative Stress

Share to Reactive Oxygen Species

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 27486766
DOI: 10.18632/oncotarget.10921
PMCID: PMC5302963

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells.PMID 27486766Read ↗

Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cells.Semantic proximity Read ↗

ARID1A in Gynecologic Precancers and Cancers.Semantic proximity Read ↗

ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.Semantic proximity Read ↗

Targeting ARID1A mutations in cancer.Semantic proximity Read ↗

Inhibition of PRMT5 triggers synthetic lethality in ARID1A-deficient endometrial cancer cells by promoting aberrant R-loop accumulationSemantic proximity Read ↗

Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.Semantic proximity Read ↗

Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cellsSemantic proximity Read ↗

Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.Semantic proximity Read ↗

Potential therapeutic targets in ARID1A-mutated cancers.Semantic proximity Read ↗

ARID1A gene mutation in ovarian and endometrial cancers (Review).Semantic proximity Read ↗

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor TherapySemantic proximity Read ↗

34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.